Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889703604> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2889703604 abstract "10554 Background: BEV has an established safety profile in adults, but long-term data in children are limited. This analysis examined the effects of BEV on growth/development in pediatric/adolescent pts. Methods: Data (height, weight, body mass index [BMI], bone age data) were pooled (5 trials): NCT00643565 (Ph2/soft tissue sarcoma); NCT01390948 (Ph2/high-grade glioma); NCT00085111 (Ph1/refractory solid tumors); NCT00667342 (Ph2/osteosarcoma); NCT00381797 (Ph2/glioma, medulloblastoma, ependymoma). Pts (<18 yrs old) received ≥1 dose of BEV + chemotherapy (CT) (n=268) or CT alone (n=135). Analyses were exploratory/descriptive. Reference growth data: WHO (<2 yrs); Centres for Disease Control (≥2 yrs). Results: Across the trials, mean number of BEV administrations per pt ranged 5.6–19.9 (dose 5–15mg/kg every 2/3 weeks). Median follow-up time, months (range): BEV+CT, 37.9 (2.4–64.2); CT, 22.9 (2.8–69.2). At baseline, median height, weight, and BMI were close to that of the reference population (mean standard deviation scores [SDS] close to 0). Over 60 months, a slight decline was observed in the mean SDS for height and weight in both arms in this cohort with different tumors/treatments (Table), but remained within normal range of healthy children. Trends were similar for BMI. No delay in growth velocity or bone age in BEV-treated pts vs CT only was observed up to 3 yrs, regardless of age/gender. A subgroup analysis of pts in the growth hormone-dependent development phase was consistent with the overall results. Conclusions: In this analysis, BEV inclusion in the treatment regimen did not have a negative impact on pediatric growth/development beyond that of CT alone. [Table: see text]" @default.
- W2889703604 created "2018-09-27" @default.
- W2889703604 creator A5002190565 @default.
- W2889703604 creator A5013529173 @default.
- W2889703604 creator A5016827658 @default.
- W2889703604 creator A5028460227 @default.
- W2889703604 creator A5038954872 @default.
- W2889703604 creator A5043001715 @default.
- W2889703604 creator A5045180889 @default.
- W2889703604 creator A5048911676 @default.
- W2889703604 creator A5051922909 @default.
- W2889703604 creator A5059171474 @default.
- W2889703604 creator A5062090005 @default.
- W2889703604 creator A5080040564 @default.
- W2889703604 date "2017-05-20" @default.
- W2889703604 modified "2023-10-02" @default.
- W2889703604 title "Long-term growth and development in 268 bevacizumab (BEV)-treated and 135 control pediatric/adolescent patients (pts): An integrated analysis." @default.
- W2889703604 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.10554" @default.
- W2889703604 hasPublicationYear "2017" @default.
- W2889703604 type Work @default.
- W2889703604 sameAs 2889703604 @default.
- W2889703604 citedByCount "0" @default.
- W2889703604 crossrefType "journal-article" @default.
- W2889703604 hasAuthorship W2889703604A5002190565 @default.
- W2889703604 hasAuthorship W2889703604A5013529173 @default.
- W2889703604 hasAuthorship W2889703604A5016827658 @default.
- W2889703604 hasAuthorship W2889703604A5028460227 @default.
- W2889703604 hasAuthorship W2889703604A5038954872 @default.
- W2889703604 hasAuthorship W2889703604A5043001715 @default.
- W2889703604 hasAuthorship W2889703604A5045180889 @default.
- W2889703604 hasAuthorship W2889703604A5048911676 @default.
- W2889703604 hasAuthorship W2889703604A5051922909 @default.
- W2889703604 hasAuthorship W2889703604A5059171474 @default.
- W2889703604 hasAuthorship W2889703604A5062090005 @default.
- W2889703604 hasAuthorship W2889703604A5080040564 @default.
- W2889703604 hasConcept C121332964 @default.
- W2889703604 hasConcept C126322002 @default.
- W2889703604 hasConcept C143998085 @default.
- W2889703604 hasConcept C187212893 @default.
- W2889703604 hasConcept C2776694085 @default.
- W2889703604 hasConcept C2777802072 @default.
- W2889703604 hasConcept C61797465 @default.
- W2889703604 hasConcept C62520636 @default.
- W2889703604 hasConcept C71924100 @default.
- W2889703604 hasConceptScore W2889703604C121332964 @default.
- W2889703604 hasConceptScore W2889703604C126322002 @default.
- W2889703604 hasConceptScore W2889703604C143998085 @default.
- W2889703604 hasConceptScore W2889703604C187212893 @default.
- W2889703604 hasConceptScore W2889703604C2776694085 @default.
- W2889703604 hasConceptScore W2889703604C2777802072 @default.
- W2889703604 hasConceptScore W2889703604C61797465 @default.
- W2889703604 hasConceptScore W2889703604C62520636 @default.
- W2889703604 hasConceptScore W2889703604C71924100 @default.
- W2889703604 hasLocation W28897036041 @default.
- W2889703604 hasOpenAccess W2889703604 @default.
- W2889703604 hasPrimaryLocation W28897036041 @default.
- W2889703604 hasRelatedWork W2021791122 @default.
- W2889703604 hasRelatedWork W2049331029 @default.
- W2889703604 hasRelatedWork W2057573317 @default.
- W2889703604 hasRelatedWork W2077390445 @default.
- W2889703604 hasRelatedWork W2132798780 @default.
- W2889703604 hasRelatedWork W2246140328 @default.
- W2889703604 hasRelatedWork W2396544020 @default.
- W2889703604 hasRelatedWork W2509635087 @default.
- W2889703604 hasRelatedWork W2587309197 @default.
- W2889703604 hasRelatedWork W2589795422 @default.
- W2889703604 hasRelatedWork W2598145699 @default.
- W2889703604 hasRelatedWork W2598555299 @default.
- W2889703604 hasRelatedWork W2715266844 @default.
- W2889703604 hasRelatedWork W2735229934 @default.
- W2889703604 hasRelatedWork W2884657914 @default.
- W2889703604 hasRelatedWork W2891016291 @default.
- W2889703604 hasRelatedWork W2947461731 @default.
- W2889703604 hasRelatedWork W3025003528 @default.
- W2889703604 hasRelatedWork W3043822390 @default.
- W2889703604 hasRelatedWork W3046320670 @default.
- W2889703604 isParatext "false" @default.
- W2889703604 isRetracted "false" @default.
- W2889703604 magId "2889703604" @default.
- W2889703604 workType "article" @default.